October 2025 Dashboard

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA's inception, 710 negotiations have reached a letter of intent (LOI), including:

- 259 for oncology drugs
- 78 for biosimilars
- 88 for expensive drugs for rare diseases (EDRD)


Savings

Lower drug costs

pCPA activities saved jurisdictions an estimated \$4.87B in 2024-25:


- \$3.94B from brand-name drugs
- **\$935M** from generic drugs

Since 2010, cumulative savings are estimated to be \$28.8B



HTA and pCPA volumes

• There has been very high activity in the first 8 months of 2025, and the pCPA is projecting high volumes of health technology assessment (HTA) recommendations, and record volumes of negotiations engaged, and negotiations closed.



The number of files in consideration was under 20 files for


- the first time in the post-COVID era. The pCPA is committed to further decreasing the in-
- consideration timeline. Files under consideration
- creased. In August, 2025, the pCPA negotiated a record 49 files.

• The number of active negotiations has significantly in-




All pCPA timeline metrics have improved between 2020 and 2025.

- The typical months under consideration phase improved from 5.1 months to 2.1 months, a 59 % decrease, and active ne-
- gotiation timelines improved from 5.5 months to 3 months, a 46 % decrease. • Between 2020 and 2025, the total timeline improved from 11 months to 6.5 months, a 41 % decrease.
- Time under Consideration* **Active Negotiation Time Total Time***



2020, to 6.4 months in 2025 (1.5 months to engagement and 3.9 months for active negotiation).

Oncology timelines Negotiation stages in 2025



pCPA targets outlined in the brand process guidelines are approximately 2 months for file engagement, 4 months for active negotiations and 6 months combined.